Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.
about
Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income CountriesTargeted killing of virally infected cells by radiolabeled antibodies to viral proteinsNovel functions of PXR in cardiometabolic disease.Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi MetropolisCharacterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco.Hypertension and obesity as cardiovascular risk factors among HIV seropositive patients in Western KenyaErectile Dysfunction Among HIV Patients Undergoing Highly Active Antiretroviral Therapy: Dyslipidemia as a Main Risk Factor.Tenofovir disoproxil fumarate for the treatment of HIV infection.HIV protease inhibitors and obesityMetabolic syndrome in relation to cardiorespiratory fitness, active and sedentary behavior in HIV+ Hispanics with and without lipodystrophy.Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular diseaseDeficiency of PXR decreases atherosclerosis in apoE-deficient mice.Nadir CD4+, religion, antiretroviral therapy, incidence of type 2 diabetes mellitus, and increasing rates of obesity among black Africans with HIV disease.Chronic non-communicable diseases.Associations between outpatient and inpatient service use among persons with HIV infection: a positive or negative relationship?Impact of age on markers of HIV-1 diseasePrevalence of metabolic syndrome among HIV-infected patients in Ghana: A cross-sectional study.Risk of Venous Thromboembolism in Patients Infected with HIV: A Cohort Study.Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice.The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism.IGF-IR in neuroprotection and brain tumors.Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects.Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy.Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy.Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.Association of hypertension and obesity with HIV and antiretroviral therapy in a rural tertiary health center in Nigeria: a cross-sectional cohort study.Diabetes and HIV: current understanding and future perspectives.Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study.Molecular Understanding of HIV-1 Latency.Clinical markers of immunodeficiency and mechanism of immune reconstitution inflammatory syndrome and highly active antiretroviral therapy on HIV: workshop 3A.HIV-1 TAT inhibits microglial phagocytosis of Abeta peptide.Human immunodeficiency virus-associated heart failure in sub-Saharan Africa: evolution in the epidemiology, pathophysiology, and clinical manifestations in the antiretroviral era.Insulin-like growth factor-I-forkhead box O transcription factor 3a counteracts high glucose/tumor necrosis factor-α-mediated neuronal damage: implications for human immunodeficiency virus encephalitis.Lipodystrophy syndrome in HIV treatment-multiexperienced patients: implication of resistin.Epigenetic impact of endocrine disrupting chemicals on lipid homeostasis and atherosclerosis: a pregnane X receptor-centric view.Integrating community pharmacy into community based anti-retroviral therapy program: A pilot implementation in Abuja, Nigeria.Prevalence and predictors of metabolic syndrome among people living with human immunodeficiency virus (PLWHIV).Addressing the under-reporting of adverse drug reactions in public health programs controlling HIV/AIDS, Tuberculosis and Malaria: A prospective cohort study
P2860
Q26801331-6CE6878A-9189-4A78-B98E-403CA3246984Q28469068-2551181F-2004-46A7-9AFF-9F8167E512DFQ30251861-1389FA50-4ACE-4731-9157-BA89CF45F254Q33751516-ADCE8890-E448-459C-A154-FEDCEFBB71D8Q33957908-2CC0DA09-E84D-46C6-A0B3-D6D394EBD9C6Q33968354-51AF2817-68C5-4F0A-B056-95FF5209A55CQ34286607-30859109-2B4D-4B73-BF3D-6DDC711C3D97Q34569309-3708BA5B-CA92-4D51-A7B3-A49BB058BA3BQ34792983-9A23DC0B-24E5-4DA0-91E8-47388DEF41C4Q35084964-60EDA454-3821-4235-94AD-B26BC0EC0BEEQ35104006-36D6AF2F-8C5D-4348-A249-48C294C7E80EQ35152206-64AD110D-2C9C-4B48-8339-5D165E726253Q36444419-3538237A-4B52-48D9-82A7-673CCF511C9DQ36561181-74A0DEF9-5F49-4BF8-BE71-92DAC867A2F2Q36570347-831EDB56-826F-42A5-829F-A2D9DC145A65Q36763762-FEED4E3B-12D1-4C0D-B529-C46A225E19D4Q36915645-AA20E8DA-AF09-443A-959E-E6F163B1616CQ37007898-CE446EE5-355C-405C-ACE1-4D7BED94883EQ37337474-FC1BEA05-D37B-4D1A-B42D-3884A89C9459Q37400616-067571E0-339F-4A5D-BEC1-7CA656939238Q37409955-2D3B6E23-ABFE-4B60-8269-727D138CBD61Q37418053-B1039FDF-E8B4-4E0C-8371-149DFF02B087Q37423408-6AD626AF-AF8D-4CFE-81B8-AC62D2CD4CDBQ37492492-1D18EB79-0BAB-4015-B242-76990D457E88Q37644561-77234858-752C-4F63-A336-0B321146FA2DQ37660222-0033372E-260F-4AC8-AFE7-3D5E94A75EDCQ38085218-99E5FD03-16E7-4491-802B-A21A07B24892Q38733997-5BB19C8A-B730-4A6A-88A0-1965A15F8EDDQ39622803-D359999D-C56A-46AF-BEC8-C169319C1A27Q39767247-41C41A82-9342-4A68-A5BE-E94FD16C01D9Q40048514-0ECF802A-2CBA-4D07-985A-DFEB74EF3353Q40073553-CE0EE340-AF9D-48C1-816A-079534902E7EQ41821482-B6B9A87A-F8AE-4CED-99F8-EA56A51977D4Q42228156-939F033B-18B9-4991-A4FB-8414839A6234Q47100840-2F527070-3F49-455A-A32C-098DC66884BCQ47556037-1C89DC67-EF53-4838-92FE-89EB2F9789BFQ50308497-E7EF9A9F-2537-4069-86AE-9C1BAC2FC0CCQ56341955-2B83D2A5-15FB-4111-B4A1-D63809A571D7
P2860
Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Metabolic and cardiovascular c ...... ral therapy for HIV infection.
@ast
Metabolic and cardiovascular c ...... ral therapy for HIV infection.
@en
type
label
Metabolic and cardiovascular c ...... ral therapy for HIV infection.
@ast
Metabolic and cardiovascular c ...... ral therapy for HIV infection.
@en
prefLabel
Metabolic and cardiovascular c ...... ral therapy for HIV infection.
@ast
Metabolic and cardiovascular c ...... ral therapy for HIV infection.
@en
P1433
P1476
Metabolic and cardiovascular c ...... ral therapy for HIV infection.
@en
P2093
Giuseppe Barbaro
P356
10.2174/157016206775197664
P577
2006-01-01T00:00:00Z